Actively Recruiting
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-22
83
Participants Needed
10
Research Sites
573 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
C
Cornell University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
CONDITIONS
Official Title
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed T or NK cell lymphoma
- For CTCL, stage IB disease or higher
- Relapsed or refractory after at least one systemic therapy (exceptions discussed with investigator)
- Age 18 or older
- ECOG performance status 0 to 2
- Measurable disease by lymphoma classification or blood/marrow tests
- Previous systemic anti-cancer therapy stopped at least 2 weeks before treatment
- Allowed steroid use tapered to 20mg or less before starting ruxolitinib
- Topical steroids allowed for CTCL
- Required blood counts: ANC ≥1.0/mm³ or ≥0.5/mm³ if baseline neutropenia, platelets ≥100x10⁹/L or ≥50x10⁹/L if related to lymphoma, hemoglobin ≥8g/dL
- Patients with LGL or T-PLL not required to meet minimum ANC or hemoglobin
- Liver function within specified limits or adjusted if related to lymphoma or Gilbert's syndrome
- Creatinine clearance ≥30 mL/min or 15-29 mL/min if platelets ≥150x10⁹/L
- Negative hepatitis B PCR if positive antibody or antigen with required prophylaxis
- HIV patients allowed if on anti-retroviral treatment with no active infections
You will not qualify if you...
- Serious medical condition, lab abnormality, or psychiatric illness preventing informed consent
- Uncontrolled illnesses such as active infection, uncontrolled diabetes, significant lung or heart problems, or conditions limiting study compliance
- ECOG performance status greater than 2
- Prior treatment with ruxolitinib
- Receiving systemic therapy for another primary cancer except T-cell lymphoma
- Women of reproductive potential must have a negative pregnancy test
- Female reproductive potential defined as sexually mature without hysterectomy or bilateral oophorectomy and not naturally postmenopausal for 24 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
University of Miami
Miami, Florida, United States
Active, Not Recruiting
2
Northwestern Medicine (Data collection and specimen analysis)
Chicago, Illinois, United States, 60611
Active, Not Recruiting
3
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Active, Not Recruiting
4
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
5
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
6
Memorial Sloan Kettering Commack
Commack, New York, United States, 11725
Actively Recruiting
7
Memorial Sloan Kettering Westchester
Harrison, New York, United States, 10604
Actively Recruiting
8
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
9
Weill Cornell Medical College
New York, New York, United States
Active, Not Recruiting
10
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
A
Alison Moskowitz, MD
CONTACT
S
Steven Horwitz, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here